Accurate estimation of the Lung Shunt Fraction (LSF) is a standard of care in yttrium-90 (90Y) radioembolization treatment planning to prevent excessive lung irradiation due to arterio-venous shunting in the liver. LSF is assessed using 99mTc macroaggregated albumin (99mTc-MAA) imaging, but this approach adds risk, complexity, and expense to the treatment planning. This study investigates the potential of Contrast-Enhanced Computed Tomography (CECT) as a non-invasive alternative for LSF estimation. Methods We developed a novel metric to estimate the LSF from differences between CECT phases, based on the premise that LSF results from tumor angiogenesis and arterio-venous shunting that create excessive local opacity in the CECT arterial phase. Hypervascular volumes were identified by subtracting the portal phase from the arterial phase and contouring the corresponding regions using an density threshold. The perfused volume corresponded to the lobe and to the volume injected with 99mTc-MAA. We conducted a retrospective analysis involving 30 liver cancer patients who underwent 4-phase liver CECT and 99mTc-MAA imaging prior to 90Y radioembolization to study several markers based on the subtraction images. The patient cohort included several types of liver tumors (primary or metastatic), predominantly hepatocellular carcinoma. Correlations between the hypervascular-to-perfused volume ratio from CECT and LSF values from standard-of-care 99mTc-MAA planar imaging were assessed. Results The strongest correlation was obtained between the hypervascular-to-perfused volume ratio from CECT and LSF values from 99mTc-MAA planar gamma imaging (R^2=0.95). The best correlation was demonstrated when the hypervascular volume was corrected by the hypoxic volume and then normalized by the perfused volume. In contrast, the tumor volume did not show a strong correlation with LSF (R^2=0.38). Moreover, the predictive power of the hypervascular-to-perfused volume ratio on LSF demonstrated a 1-sigma uncertainty of 3%. Conclusion CECT-based LSF estimation shows promise as a non-invasive alternative to 99mTc-MAA imaging in 90Y treatment planning. Further validation with prospective studies on larger cohorts is necessary to confirm the accuracy and safety of this approach.

The authors have declared no competing interest.

This work has been funded by a UC Davis Comprehensive Cancer Center pilot award (CCSG NCI P30 CA093373)

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of California Davis Institutional Review Board. Ethical approval was given.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Some data produced in the present study are available upon reasonable request to the authors